amcure leverages its in-depth knowledge of CD44 target biology to develop a novel therapeutic approach to treat metastatic squamous tumors. In cancer, blocking the extracellular target CD44v6 has a beneficial effect on several relevant receptor tyrosine kinase pathways. Our first-in-class CD44v6-inhibitor AMC303 entered clinical development in solid tumors in Q4 2016.
Spin-off from the Karlsruhe Instituteof Technology (KIT)
CD44v6 inhibitor AMC303, a potent and selective inhibitor of multiple receptor tyrosine kinases
First-in-Class molecule AMC303 in Phase I/Ib study in cancer patients
amcure is sponsored by a grant from the German Ministry of Education and Research
Short description: Development of a novel compound for the treatment of metastasizing cancers
Support code: 031B0052
© 2019 amcure GmbH | Imprint/Impressum | Privacy Policy/Datenschutzerklärung
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.